Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000192648 | SCV000246848 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2014-12-19 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000790660 | SCV000338900 | pathogenic | not provided | 2016-01-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000192648 | SCV001235090 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2024-01-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg110Profs*18) in the CAPN3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CAPN3 are known to be pathogenic (PMID: 10330340, 15689361). This variant is present in population databases (rs797045427, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with limb girdle muscular dystrophy (PMID: 18055493, 20694146). ClinVar contains an entry for this variant (Variation ID: 210563). For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000790660 | SCV001246424 | pathogenic | not provided | 2021-06-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000790660 | SCV003813151 | pathogenic | not provided | 2022-05-09 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000192648 | SCV000797748 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2018-02-08 | no assertion criteria provided | clinical testing | |
Baylor Genetics | RCV003462299 | SCV004213797 | pathogenic | Muscular dystrophy, limb-girdle, autosomal dominant 4 | 2023-03-15 | flagged submission | clinical testing |